Newron Pharmaceuticals Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-13.24	15.84	-16.22	-17.49	-14.9
Depreciation & Amortization	0.17	0.19	0.2	0.2	0.21
Stock-Based Compensation	0.21	0.26	0.2	0.48	0.76
Other Operating Activities	5.58	3.85	4.17	3.83	2.75
Change in Accounts Receivable	43.34	-44.22	-1.31	-0.88	1.75
Change in Accounts Payable	-4.42	2.63	0.58	0.58	-3.95
Change in Other Net Operating Assets	0.7	3.84	2.24	2.19	1.93
Operating Cash Flow	32.35	-17.61	-10.14	-11.09	-11.45
Capital Expenditures	-0.05	-0.01	-0.01	-0.02	-0.02
Sale (Purchase) of Intangibles	-0	-	-	-	-
Investment in Securities	-13.62	3.17	3.26	-0.3	8.44
Investing Cash Flow	-13.66	3.16	3.25	-0.32	8.42
Long-Term Debt Issued	-	-	-	-	15
Long-Term Debt Repaid	-13.78	-0.19	-0.19	-0.19	-0.17
Net Debt Issued (Repaid)	-13.78	-0.19	-0.19	-0.19	14.83
Issuance of Common Stock	0.35	15.41	-	-	-
Other Financing Activities	-	-0.17	-	-	-
Financing Cash Flow	-13.43	15.05	-0.19	-0.19	14.83
Net Cash Flow	5.25	0.6	-7.09	-11.6	11.81
Free Cash Flow	32.3	-17.63	-10.15	-11.11	-11.47
Free Cash Flow Margin	168.89%	-34.30%	-112.08%	-182.31%	-198.98%
Free Cash Flow Per Share	1.62	-0.86	-0.57	-0.62	-0.64
Cash Interest Paid	3.29	1.9	1.2	1.23	0.87
Levered Free Cash Flow	39.32	-26.67	-9.22	-9.64	-10.04
Unlevered Free Cash Flow	42.07	-23.95	-6.61	-7.17	-8.22
Change in Working Capital	39.62	-37.75	1.51	1.89	-0.26

Source: S&P Global Market Intelligence. Standard template. Financial Sources.